Clinical Trials Logo

HIV/AIDS clinical trials

View clinical trials related to HIV/AIDS.

Filter by:

NCT ID: NCT03282890 Completed - HIV/AIDS Clinical Trials

Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs

CHRP-BB
Start date: November 20, 2017
Phase: N/A
Study type: Interventional

This study will evaluate the efficacy and cost-effectiveness of CHRP-BB - an integrated bio-behavioral approach that incorporates the use of PrEP - with an evidence-based behavioral approach aimed at enhancing PrEP adherence and HIV risk reduction among high risk PWUD.

NCT ID: NCT03282799 Completed - Contraception Clinical Trials

Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women

Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the frequency of ovulation and cervical mucus quality of HIV-infected women on efavirenz (EFV)-based antiretroviral therapy (ART) using either a single etonogestrel (ENG) implant or two ENG implants for at least one year.

NCT ID: NCT03281226 Recruiting - HIV/AIDS Clinical Trials

RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection

RIPENACTB
Start date: December 7, 2016
Phase: Phase 2
Study type: Interventional

Although tuberculosis is a treatable disease, it is currently the infectious disease with the highest mortality in the world. It is estimated that one-third of the world's population is infected. HIV is the main predisposing factor for TB development. The Brazilian Ministry of Health and the World Health Organization recommends that patients should initially be treated orally with RIPE - rifampicin (R), isoniazid (I), pyrazinamide (P) and ethambutol (E). The N-acetylcysteine (NAC) first benefit was reported during the 1960s, when it proved to be an effective mucolytic agent in individuals with cystic fibrosis. Later, a new role arose when investigating its therapeutic potential in acetaminophen intoxication. Cleavage of the acetyl group makes cysteine available for later incorporation into glutathione synthesis, decreased in hepatic injury caused by acetaminophen. This mechanism causes NAC to have an indirect antioxidant effect, which aroused an interest in studying the effect in diseases that occur with oxidative stress. TB and HIV/Aids are also diseases with chronic inflammation. The present study aims to evaluate the effects of NAC as a adjuvant therapy in the treatment of TB. This is a phase II randomized clinical trial in which the safety and tolerability of NAC as adjunctive therapy for TB treatment will be assessed. Fifty-six patients will be randomized into two groups. The first group will receive the standard tuberculosis treatment as recommended by the Brazilian Ministry of Health (RIPE); the second will receive in addition to this treatment 1200mg of NAC per day for two months. In this way, microscopy and culture conversion rate to mycobacteria at 8 weeks, levels of glutathione and biomarkers of immune activation and inflammation in case of TB with or without NAC will be monitored.

NCT ID: NCT03279185 Recruiting - HIV/AIDS Clinical Trials

Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite

AMP Up Lite
Start date: November 1, 2017
Phase:
Study type: Observational

This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition to adulthood.

NCT ID: NCT03276338 Completed - HIV/AIDS Clinical Trials

Using CBPR to Reduce HIV Risk Among Immigrant Latino MSM

HOLA
Start date: April 1, 2011
Phase: N/A
Study type: Interventional

The intervention is based on social cognitive theory and theory of empowerment education and was developed using community-based participatory research (CBPR). This study is a result of a long-term community-university partnership that has used and will continue to use CBPR throughout all phases of research. A total of 21 Latino MSM in rural NC have been screened and recruited to serve as LHAs. The CBPR partnership selected LHAs based on qualities of natural helpers and informal leaders and having existing social networks of other Latino MSM. Eight members of each LHA's social network have been screened and recruited to participate as well. The LHAs, coupled with their social networks, have been randomized to intervention or delayed-intervention groups. LHAs (n=11) in the intervention group were trained and serve as LHAs within their social networks in Year 2. Delayed-intervention LHAs (n=10) receive the same LHA training and serve as LHAs within their social networks in Year 3. Quantitative assessment data is collected from each LHA (n=21) and the 8 members of his social network (n=189) longitudinally at: (1) baseline, (2) immediate post-intervention, and (3) 12-month follow-up. This is an "intent-to-treat" study, in which participant data are analyzed based on their randomization group. The investigators hypothesize that participants in the HIV prevention intervention, relative to those in the delayed intervention comparison group, will demonstrate (1) increased self-reported use of condoms during sexual intercourse and (2) increased self-reported HIV testing. The results and products from this study will be disseminated to inform public health practice, research, and policy. Results and products will include: (1) a Spanish-language intervention that is: culturally congruent and gender-specific; designed to reduce HIV risk among Latino MSM; and ready for dissemination and adaptation; (2) a deeper understanding of HIV risk and intervention among Latino MSM; and (3) insight into a CBPR process that includes community members, organizational representatives, and academic researchers.

NCT ID: NCT03270709 Terminated - Clinical trials for Vitamin D Deficiency

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

Start date: April 11, 2018
Phase: Phase 1
Study type: Interventional

Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The primary goal is to improve innate immune host response to infection in patients already at high risk by virtue of HIV and smoking status.

NCT ID: NCT03268551 Completed - Chronic Pain Clinical Trials

MEMO-Medical Marijuana and Opioids Study

Start date: September 4, 2018
Phase:
Study type: Observational

The study will examine how medical cannabis use affects opioid analgesic use over time, with particular attention to THC/CBD content, HIV outcomes, and severe adverse events.

NCT ID: NCT03268109 Recruiting - Clinical trials for Cognitive Impairment

COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old

COGITO
Start date: September 22, 2017
Phase:
Study type: Observational

Despite combined antiretroviral therapy (cART), milder forms of HIV-associated neurocognitive disorders (HAND) persist in 20-50% of persons living with HIV (PLHIV). Since more PLH are at risk for HAND due to aging, the frequency of HAND in PLHIV ≥ 65 years old is important to quantify for planning early intervention to attenuate both functional and occupational disabilities due to cognitive impairment.

NCT ID: NCT03267407 Active, not recruiting - HIV/AIDS Clinical Trials

Vietnam Cryptococcal Retention in Care Study - Version 2.1

Start date: August 14, 2015
Phase: N/A
Study type: Observational

This is a multicenter prospective cohort evaluation of the implementation of a cryptococcal antigen (CrAg) screening program at selected outpatient HIV clinics (OPCs) and network laboratories in Vietnam.

NCT ID: NCT03262402 Completed - HIV/AIDS Clinical Trials

Effects of Periodontal Treatment on HIV-infected Patients

Start date: July 2, 2017
Phase: N/A
Study type: Interventional

Periodontal diseases, such as chronic periodontitis (CP), frequently occur in immunosuppressed patients, including HIV-infected patients. The immunosuppression resulted by the HIV infection can justify the high frequency and the difficult in controlling the CP in this group of patients, raising the possibility of additional factors associated to the development of CP in HIV patients. The aim of this study is to determine factors that can be involved in the CP pathogenesis in HIV patients, including Candida spp presence, and biomarkers involved on the inflammatory response against the microorganisms.